Ami Fadia Reiterates Buy on Revolution Medicines, Slightly Lowers Price Target to $183 Amid Higher Non‑Cash Expenses and Expanded RASolute 301 Trial

TIPRANKS05-07

Ami Fadia, an analyst from Needham, reiterated the Buy rating on Revolution Medicines. The associated price target was lowered to $183.00. Ami Fadi...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2633182791?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-07 15:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2633182791","market":"nz","top_or_hot":-1,"title":"Ami Fadia Reiterates Buy on Revolution Medicines, Slightly Lowers Price Target to $183 Amid Higher Non‑Cash Expenses and Expanded RASolute 301 Trial","media":"TIPRANKS","content":"<div>\n<p>Ami Fadia, an analyst from Needham, reiterated the Buy rating on Revolution Medicines. The associated price target was lowered to $183.00. Ami Fadi...</p>\n\n<a href=\"https://www.tipranks.com/news/ratings/ami-fadia-reiterates-buy-on-revolution-medicines-slightly-lowers-price-target-to-183-amid-higher-non‑cash-expenses-and-expanded-rasolute-301-trial-ratings-news?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n","source":"tipranks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ami Fadia Reiterates Buy on Revolution Medicines, Slightly Lowers Price Target to $183 Amid Higher Non‑Cash Expenses and Expanded RASolute 301 Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmi Fadia Reiterates Buy on Revolution Medicines, Slightly Lowers Price Target to $183 Amid Higher Non‑Cash Expenses and Expanded RASolute 301 Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-07 15:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/ratings/ami-fadia-reiterates-buy-on-revolution-medicines-slightly-lowers-price-target-to-183-amid-higher-non‑cash-expenses-and-expanded-rasolute-301-trial-ratings-news?utm_source=itigerup.com&utm_medium=referral><strong>TIPRANKS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ami Fadia, an analyst from Needham, reiterated the Buy rating on Revolution Medicines. The associated price target was lowered to $183.00. Ami Fadi...</p>\n\n<a href=\"https://www.tipranks.com/news/ratings/ami-fadia-reiterates-buy-on-revolution-medicines-slightly-lowers-price-target-to-183-amid-higher-non‑cash-expenses-and-expanded-rasolute-301-trial-ratings-news?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RVMD","symbol_name":"Revolution Medicines, Inc.","start_time":0,"source_url":"https://www.tipranks.com/news/ratings/ami-fadia-reiterates-buy-on-revolution-medicines-slightly-lowers-price-target-to-183-amid-higher-non‑cash-expenses-and-expanded-rasolute-301-trial-ratings-news?utm_source=itigerup.com&utm_medium=referral","article_id":"2633182791","we_media_id":null,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/ami-fadia-reiterates-buy-on-revolution-medicines-slightly-lowers-price-target-to-183-amid-higher-non‑cash-expenses-and-expanded-rasolute-301-trial-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2633182791","pubTimestamp":1778139324,"columns":[],"sourceInfo":{"source_id":"tipranks_highlight","name":"Tipranks"},"weMediaInfo":null,"summary":"Ami Fadia, an analyst from Needham, reiterated the Buy rating on Revolution Medicines. The associated price target was lowered to $183.00. Ami Fadi...","collect":0,"end_time":0,"defaultTopTitle":"tipranks.com","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"RVMD":"Revolution Medicines, Inc."},"translate_title":"Ami Fadia重申买入Revolution Medicines，由于非现金支出增加和RASolute 301试验扩大，将目标价小幅下调至183美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVMD":1.5},"content_text":"Ami Fadia, an analyst from Needham, reiterated the Buy rating on Revolution Medicines. The associated price target was lowered to $183.00. Ami Fadi...","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2633182791","isCrawlerRequest":true}